Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2026)

Camp4 Therapeutics' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $117.8 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 50.44% to $117.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $318.3 million, a 219.3% increase, with the full-year FY2025 number at $117.8 million, up 50.44% from a year prior.
  • Liabilities and Shareholders Equity hit $117.8 million in Q4 2025 for Camp4 Therapeutics, up from $86.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CAMP hit a ceiling of $117.8 million in Q4 2025 and a floor of $21.4 million in Q3 2024.
  • Historically, Liabilities and Shareholders Equity has averaged $67.6 million across 3 years, with a median of $62.8 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 42.52% in 2024 and later soared 304.4% in 2025.
  • Tracing CAMP's Liabilities and Shareholders Equity over 3 years: stood at $54.9 million in 2023, then surged by 42.52% to $78.3 million in 2024, then soared by 50.44% to $117.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CAMP at $117.8 million in Q4 2025, $86.4 million in Q3 2025, and $51.3 million in Q2 2025.